Circle Pharma vs Pliant Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Circle Pharma logo

Circle Pharma

NicheLife Sciences & BioTech

Cell-Permeable Macrocycle Oncology Therapeutics

Circle Pharma develops orally deliverable macrocycle drug candidates targeting intracellular protein-protein interactions in cancer; raised $90M Series B in 2023 led by Novo Holdings and Foresite Capital; headquartered in San Francisco;

About

Circle Pharma is a clinical-stage biopharmaceutical company founded in 2016 by Matthew Jacobson, Siegfried Bhagwati, and Grace Aldrovandi, headquartered in San Francisco, California. The company is developing a new class of therapeutics — cell-permeable macrocycles — designed to inhibit intracellular protein-protein interactions (PPIs) that have historically been considered "undruggable." Protein-protein interactions control critical cellular processes including cell division, apoptosis (programmed cell death), and gene expression. Dysregulation of these interactions drives many cancers, but their large, flat interaction surfaces are difficult to block with small molecules, and biologics (antibodies) cannot cross cell membranes to reach intracellular targets. Circle Pharma's macrocycles are medium-sized ring-shaped molecules engineered to be both cell-permeable and orally bioavailable — a combination rarely achieved — enabling them to reach and inhibit these targets.

Full profile
Pliant Therapeutics logo

Pliant Therapeutics

ChallengerBioTech

Fibrotic Disease

Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.

AI VisibilityBeta
Overall Score
B62
Category Rank
#1 of 1
AI Consensus
62%
Trend
up
Per Platform
ChatGPT
54
Perplexity
60
Gemini
55

About

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.

Full profile

Key Details

Category
Cell-Permeable Macrocycle Oncology Therapeutics
Fibrotic Disease
Tier
Niche
Challenger
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Pliant Therapeutics
Fibrotic Disease

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.